Breast Cancer Brain Metastases: Implementation and Characterization of a Mouse Model Relying on Malignant Cells Inoculation in the Carotid Artery

Cells. 2023 Aug 16;12(16):2076. doi: 10.3390/cells12162076.

Abstract

Breast cancer (BC) brain metastases (BCBM) is a severe condition frequently occurring in the triple-negative subtype. The study of BCBM pathogenesis and treatment has been hampered by the difficulty in establishing a reliable animal model that faithfully recapitulates the preferential formation of brain metastases. The injection of BC cells in the carotid artery of mice has been proposed but the procedure is challenging, with the metastatic pattern being scarcely characterized. In this work, we thoroughly describe an improved procedure, highlighting the tricks and challenges of the process, and providing a characterization of the brain and peripheral metastatic pattern at the cellular and molecular level. Triple-negative BC (4T1) cells were inoculated in the common carotid artery of BALB/c mice. Brains and peripheral organs were harvested at 7-14 days for the histological characterization of the metastases' pattern and the immunofluorescence analysis of specific markers. With our surgical procedure, both mouse death and procedure-associated weight loss were negligible. Brain metastases mostly occurred in the hippocampus, while sparse peripheral lesions were only detected in the lungs. Brain-colonizing BC cells presented proliferative (Ki-67) and epithelial (pan-cytokeratin and tomato lectin) features, which account for metastases' establishment. The presented surgical approach constitutes an important and reliable tool for BCBM studies.

Keywords: Ki-67; blood–brain barrier; brain metastases; breast cancer; cytokeratin; intracarotid injection; mouse model; peripheral metastases; proliferation; tomato lectin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Neoplasms*
  • Carotid Artery, Common
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Triple Negative Breast Neoplasms*

Grants and funding

This research was funded by the Portuguese Foundation for Science and Technology (FCT), Portugal (FCT-PTD/MED-ONC/29402/2017, UIDB/04138/2020, UIDP/04138/2020 and SFRH/BD/145522/2019); Pfizer (68977633); Magyar Tudományos Akadémia (NAP2022-I-7/2022) and the National Research Development and Innovation Office (NKFIH), Hungary (K135425 and TKP2021-EGA-09); and the Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania (PN-III-P4-ID-PCE-2020-1529).